Ahmed Souka, MD
Interventional Cardiology · Topeka, KSNPI 1790154185
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Shockwave Medical, Inc at 25.3% of the total.
Across 235 payments — averaging $157.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$9K
- Edwards Lifesciences$8K
- Boston Scientific$6K
- Angiodynamics, Inc.$4K
- Penumbra, Inc.$3K
- Abbott$2K
- plus $5K from 18 others
What the payments were for
- Speaking & faculty fees$6,60018%
- Grants$3491%
- Travel & lodging$18,92751%
- Food & beverage$10,94830%
- Education$2201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 22 | $9,377 |
| Edwards Lifesciences | 55 | $7,841 |
| Boston Scientific | 36 | $6,242 |
| Angiodynamics, Inc. | 14 | $4,269 |
| Penumbra, Inc. | 14 | $2,584 |
| Abbott | 29 | $2,205 |
| Medtronic | 21 | $1,695 |
| W. L. Gore & Associates, Inc. | 10 | $1,694 |
| Cardiovascular Systems Inc. | 2 | $204 |
| Abiomed | 2 | $195 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $160 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $129 |
| Amgen | 6 | $106 |
| Irhythm Technologies, Inc. | 3 | $70 |
| Novo Nordisk | 3 | $54 |
| Merck | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Stryker | 1 | $27 |
| AstraZeneca | 1 | $22 |
| Novartis | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Pfizer | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,916
- AngioVac$4,096
- SAPIEN 3 Ultra RESILIA$3,190
- GENERAL VASCULAR ACCESS$3,150
- Indigo System$2,136
- GORE CARDIOFORM Septal Occluder$1,574
- AMPLATZER AMULET$1,265
- CoreValve Evolut$969
- VersaCross Access Solution$683
- GENERAL ATHERECTOMY$463
- Edwards SAPIEN 3 Transcatheter Heart Valve$233
- AVVIGO Guidance System$231
- Resolute$144
- CARDIOMEMS$143
- Xience Sierra Coronary Stent$136
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$132
- Rotablator Rotational Atherectomy System Console Kit$121
- Diamondback Coronary$120
- ARCALYST$115
How this compares
$37,044 in reported general payments places this provider in the 85th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $29,657 |
| XareltoRivaroxaban | 20 | $18,334 |
| Atorvastatin Calcium | 114 | $851 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 47 | $491 |
| Metoprolol Succinate | 46 | $457 |
| Pravastatin Sodium | 24 | $400 |
| Amlodipine Besylate | 71 | $268 |
| Spironolactone | 15 | $246 |
| Metoprolol Tartrate | 65 | $230 |
| Losartan Potassium | 35 | $227 |
| Nitroglycerin | 15 | $185 |
| ClopidogrelClopidogrel Bisulfate | 18 | $180 |
| Rosuvastatin Calcium | 24 | $165 |
| Furosemide | 31 | $117 |
| Carvedilol | 41 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $29,65736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Topeka
- Sindhu AvulaTopeka$18K
- Seshu RaoTopeka$6K
- Jack JonesTopeka$3K
- Bashar AbabnehTopeka$2K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Priyantha RanaweeraManhattan$41K
- Mark WileyKansas City$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.